KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Equity Income (2020 - 2025)

Historic Equity Income for Amgen (AMGN) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Amgen's Equity Income rose 13571.43% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.0 million, marking a year-over-year decrease of 1764.71%. This contributed to the annual value of $10.0 million for FY2024, which is 19090.91% up from last year.
  • Latest data reveals that Amgen reported Equity Income of $10.0 million as of Q3 2025, which was up 13571.43% from -$18.0 million recorded in Q2 2025.
  • Over the past 5 years, Amgen's Equity Income peaked at $97.0 million during Q4 2021, and registered a low of -$305.0 million during Q1 2022.
  • Its 5-year average for Equity Income is -$42.8 million, with a median of -$11.0 million in 2025.
  • Its Equity Income has fluctuated over the past 5 years, first crashed by 147142.86% in 2022, then skyrocketed by 14285.71% in 2024.
  • Amgen's Equity Income (Quarter) stood at $97.0 million in 2021, then tumbled by 283.51% to -$178.0 million in 2022, then skyrocketed by 84.27% to -$28.0 million in 2023, then soared by 96.43% to -$1.0 million in 2024, then skyrocketed by 1100.0% to $10.0 million in 2025.
  • Its Equity Income was $10.0 million in Q3 2025, compared to -$18.0 million in Q2 2025 and -$11.0 million in Q1 2025.